Search hospitals > Minnesota > Saint Paul
Minnesota Oncology Hematology PA-Maplewood
Claim this profileSaint Paul, Minnesota 55109
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Ovarian Cancer
475 reported clinical trials
14 medical researchers
Summary
Minnesota Oncology Hematology PA-Maplewood is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Ovarian Cancer and other specialties. Minnesota Oncology Hematology PA-Maplewood is involved with conducting 475 clinical trials across 504 conditions. There are 14 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.Area of expertise
1Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
David M. KingPark Nicollet Clinic - Saint Louis Park8 years of reported clinical research
Expert in Lung Cancer
Expert in Breast Cancer
104 reported clinical trials
167 drugs studied
Daniel M. AndersonAbbott-Northwestern Hospital6 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
61 reported clinical trials
110 drugs studied
Yan JiRegions Hospital2 years of reported clinical research
Studies Breast Cancer
Studies Cancer
32 reported clinical trials
78 drugs studied
Pamala A. PawloskiPark Nicollet Clinic - Saint Louis Park6 years of reported clinical research
Studies Cancer
Studies Relapse
14 reported clinical trials
19 drugs studied
Clinical Trials running at Minnesota Oncology Hematology PA-Maplewood
Lung Cancer
Breast Cancer
Prostate Cancer
Colorectal Cancer
Esophageal cancer
Ovarian Cancer
Cancer
Breast cancer
Pancreatic Cancer
Bladder Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting2 awards Phase 315 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Minnesota Oncology Hematology PA-Maplewood?
Minnesota Oncology Hematology PA-Maplewood is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Ovarian Cancer and other specialties. Minnesota Oncology Hematology PA-Maplewood is involved with conducting 475 clinical trials across 504 conditions. There are 14 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Where is Minnesota Oncology Hematology PA-Maplewood located?
**Minnesota Oncology Hematology PA-Maplewood**
- **Address:** 310 Smith Ave N, Suite 100, Saint Paul, MN 55102
- **Directions:** Take I-94 E to exit 238B for US-10 E towards Maplewood. Continue on US-10 E to Smith Ave N.
Who should I call to ask about financial aid or insurance network?
**Minnesota Oncology Hematology PA-Maplewood Financial and Insurance Assistance:**
- **Financial Assistance:** Contact the Patient Benefit Representative at your clinic or call (844) 317-4673 for help with insurance claims and finding financial assistance through nationally recognized programs.
- **Insurance Inquiries:** Call (844) 317-4673 for assistance with insurance-related questions. Minnesota Oncology submits claims to most major insurance carriers on your behalf.
- **Pharmacy Inquiries:** For assistance with medications, pain management, and drug interactions, contact the Maplewood Cancer Center pharmacist at (651) 255-8480. They also help with insurance approval and obtaining financial assistance.
What insurance does Minnesota Oncology Hematology PA-Maplewood accept?
Minnesota Oncology Hematology PA-Maplewood accepts a wide range of insurance plans, including Aetna, Medicare, PPO, CMS, BCBS Blue Card, Cigna, Anthem, First Health, Wellmark, UHC Community & State - Direct, and Medica. They participate in value-based payment models with Blue Cross Blue Shield of Minnesota to deliver best-in-class results at a lower overall cost.
What awards or recognition has Minnesota Oncology Hematology PA-Maplewood received?
Minnesota Oncology Hematology PA-Maplewood, located in Saint Paul, Minnesota, is the Twin Cities' largest and most experienced cancer treatment provider. It has been designated as a Blue Distinction® Center for Cancer Care by Blue Cross Blue Shield Minnesota, highlighting its commitment to delivering high-quality, cost-effective cancer care.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.